Skip to main content
Medical information Clinical review pending

Cytogenetics

BCRABL1 Quantification by DD PCR

BCRABL1 Quantification by DD PCR measures the BCR-ABL1 fusion gene in blood, crucial for monitoring chronic myeloid leukemia (CML) treatment response. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Peripheral blood sample (usually collected in an EDTA tube). Confirm with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for this test. Confirm with the laboratory before booking.
Test priceKSh 18,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the BCRABL1 Quantification by DD PCR test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Monitoring treatment response in patients diagnosed with CML.
  • ✓Assessing minimal residual disease (MRD) in CML patients.
  • ✓Evaluating disease progression in CML.
  • ✓Guiding treatment decisions for CML.
02

In plain language

What this test helps you understand

This test is used to monitor the effectiveness of treatment for chronic myeloid leukemia (CML) by quantifying the BCR-ABL1 fusion gene. It helps assess treatment response and detect minimal residual disease.
The BCRABL1 Quantification by DD PCR test is a vital diagnostic tool used primarily in the management of chronic myeloid leukemia (CML). This test quantifies the BCR-ABL1 fusion gene, which is a significant marker in the diagnosis and monitoring of CML. Detecting this genetic abnormality helps healthcare providers tailor treatment plans effectively and monitor the patient's response to therapy.

This test measures the levels of the BCR-ABL1 fusion gene in peripheral blood samples. The presence and quantity of this gene are crucial for evaluating the disease's progression and treatment response. By utilizing the Droplet Digital PCR method, this test provides highly sensitive and specific results, allowing for accurate assessments.

Your test results will indicate the level of the BCR-ABL1 gene present in your sample. Higher levels may suggest a need for changes in your treatment plan. It is essential to discuss your results with your healthcare provider to understand their implications fully.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for this test. Confirm with the laboratory before booking.
SamplePeripheral blood sample (usually collected in an EDTA tube). Confirm with the laboratory before booking.
MethodologyDroplet Digital PCR (DD PCR).
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects the BCR-ABL1 fusion gene. Results must be interpreted in the context of the patient's clinical picture and other laboratory findings. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The BCRABL1 gene is a fusion gene created when parts of the BCR gene and the ABL1 gene join together. It is strongly associated with chronic myeloid leukemia (CML).
This test measures the amount of the BCRABL1 gene in the blood. This helps doctors monitor how well CML treatment is working and detect any signs of the disease returning or progressing.
DD PCR stands for Droplet Digital PCR. It is a highly sensitive and accurate method for measuring the quantity of specific DNA sequences, like the BCRABL1 gene.
Your doctor will interpret the results based on the level of the BCRABL1 gene detected. Lower levels generally indicate a better response to treatment. Discuss your specific results with your healthcare provider.
Yes, a doctor's prescription is required to book this test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp